Vevey / CH. (nsa) Nestle S.A. announced that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing. This agreement follows Nestle’s announcement last year that it would conduct a strategic review of Palforzia. Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer. «We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world,» said Greg Behar, CEO of Nestlé Health Science. «At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers.» There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
OTHER TOPICS FROM THIS SECTION FOR YOU:
- Axfood AB: Reports Q3-2024 Financial Results
- Fodelia Group: 2024 Time of good growth and development
- Paulig Group: starts new salsas production in Estonia
- Smucker Company: sells »Voortman« to CapVest Partners
- EPP partners with Jufeba to deliver doughnut frying solutions
- Lantmännen Group Divests Scandbio
- Albertsons Companies: Reports Q2 Fiscal 2024 Results
- Axfood AB: Acquisition of City Gross now approved
- Sweden: Lantmännen establish Biogas AB
- Apetit PLC: H1-2024 result exceeded comparison period
- DPC Dash: Continues to Unleash Massive Market Potential
- Ferraro Foods: Acquires Botticelli Food Service
- One Rock Capital completes investment in Lewis Bakeries
- Almarai agrees to acquire Hammoudeh Food Industries
- Unigrains Iberia: acquires stake in Ñaming sandwiches
- Greencore Group: upgrades full year 2024 guidance
- PFG: Completes the Acquisition of Cheney Bros.
- Conagra Brands: Reports First Quarter 2025 Results
- ICA Maxi Ängelholm to Build Sweden’s Largest In-Store Farm
- Gudrun Group: Joins Natra to Create a Leading Global Platform